Ontology highlight
ABSTRACT:
SUBMITTER: Schoels MM
PROVIDER: S-EPMC3595140 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature
Schoels Monika M MM van der Heijde Désirée D Breedveld Ferdinand C FC Burmester Gerd R GR Dougados Maxime M Emery Paul P Ferraccioli Gianfranco G Gabay Cem C Gibofsky Allan A Gomez-Reino Juan Jesus JJ Jones Graeme G Kvien Tore K TK Murakami Miho M Nishimoto Norihiro N Smolen Josef S JS
Annals of the rheumatic diseases 20121110 4
<h4>Background</h4>Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.<h4>Objective</h4>To review published evidence on safety and efficacy of IL-6i in inflamm ...[more]